183 related articles for article (PubMed ID: 8626855)
1. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas.
Derwahl M; Hamacher C; Russo D; Broecker M; Manole D; Schatz H; Kopp P; Filetti S
J Clin Endocrinol Metab; 1996 May; 81(5):1898-904. PubMed ID: 8626855
[TBL] [Abstract][Full Text] [Related]
2. Expression of functional stimulatory guanine nucleotide binding protein in nonfunctioning thyroid adenomas is not correlated to adenylate cyclase activity and growth of these tumors.
Hamacher C; Studer H; Zbaeren J; Schatz H; Derwahl M
J Clin Endocrinol Metab; 1995 May; 80(5):1724-32. PubMed ID: 7745026
[TBL] [Abstract][Full Text] [Related]
3. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
Tonacchera M; Chiovato L; Pinchera A; Agretti P; Fiore E; Cetani F; Rocchi R; Viacava P; Miccoli P; Vitti P
J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms.
Derwahl M; Manole D; Sobke A; Broecker M
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S6-9. PubMed ID: 9867188
[TBL] [Abstract][Full Text] [Related]
5. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
6. 1,25-Dihydroxyvitamin D3 attenuates adenylyl cyclase activity in rat thyroid cells: reduction of thyrotropin receptor number and increase in guanine nucleotide-binding protein Gi-2 alpha.
Berg JP; Sandvik JA; Ree AH; Sørnes G; Bjøro T; Torjesen PA; Gordeladze JO; Haug E
Endocrinology; 1994 Aug; 135(2):595-602. PubMed ID: 8033808
[TBL] [Abstract][Full Text] [Related]
7. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms.
Matsuo K; Friedman E; Gejman PV; Fagin JA
J Clin Endocrinol Metab; 1993 Jun; 76(6):1446-51. PubMed ID: 8501149
[TBL] [Abstract][Full Text] [Related]
8. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G
J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
[TBL] [Abstract][Full Text] [Related]
9. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution.
Derwahl M
J Clin Endocrinol Metab; 1996 Aug; 81(8):2783-5. PubMed ID: 8768829
[TBL] [Abstract][Full Text] [Related]
10. [Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism].
Derwahl M
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():25-8. PubMed ID: 10355046
[TBL] [Abstract][Full Text] [Related]
11. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation.
Spambalg D; Sharifi N; Elisei R; Gross JL; Medeiros-Neto G; Fagin JA
J Clin Endocrinol Metab; 1996 Nov; 81(11):3898-901. PubMed ID: 8923835
[TBL] [Abstract][Full Text] [Related]
12. Enhanced functional activity in thyroid adenomas in vitro.
Poertl S; Kirner J; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():39-40. PubMed ID: 8980999
[TBL] [Abstract][Full Text] [Related]
13. Absence of activating mutations of the genes encoding the alpha-subunits of G11 and Gq in thyroid neoplasia.
Ringel MD; Saji M; Schwindinger WF; Segev D; Zeiger MA; Levine MA
J Clin Endocrinol Metab; 1998 Feb; 83(2):554-9. PubMed ID: 9467574
[TBL] [Abstract][Full Text] [Related]
14. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter.
Tonacchera M; Agretti P; Chiovato L; Rosellini V; Ceccarini G; Perri A; Viacava P; Naccarato AG; Miccoli P; Pinchera A; Vitti P
J Clin Endocrinol Metab; 2000 Jun; 85(6):2270-4. PubMed ID: 10852462
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G
Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627
[TBL] [Abstract][Full Text] [Related]
16. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters.
Holzapfel HP; Führer D; Wonerow P; Weinland G; Scherbaum WA; Paschke R
J Clin Endocrinol Metab; 1997 Dec; 82(12):4229-33. PubMed ID: 9398745
[TBL] [Abstract][Full Text] [Related]
17. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil.
Nogueira CR; Kopp P; Arseven OK; Santos CL; Jameson JL; Medeiros-Neto G
Thyroid; 1999 Nov; 9(11):1063-8. PubMed ID: 10595453
[TBL] [Abstract][Full Text] [Related]
18. Low incidence of the stimulatory G protein alpha-subunit mutations in autonomously functioning thyroid adenomas in Japan.
Tanaka K; Nagayama Y; Takeshita A; Namba H; Yamashita S; Niwa M; Nagataki S
Thyroid; 1996 Jun; 6(3):195-9. PubMed ID: 8837326
[TBL] [Abstract][Full Text] [Related]
19. Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas.
Derwahl M
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():32-5. PubMed ID: 8980997
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
